Britain and America have agreed to a important trade agreement that will maintain zero tariffs on British pharmaceutical exports going into the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has committed to increase expenditure on drugs through the National Health Service (NHS). This move guarantees that tariffs on these crucial products will be held at zero for a timeframe of 36 months.
This agreement is in response to recent statements to hike tariffs on branded pharmaceutical imports, with potential rates floated reaching 100%.
"This deal between the Britain bolsters the worldwide climate for new treatments and establishes long-overdue equity to transatlantic medicine commerce," a statement declared.
Commercial Importance
Drugs represent one of the Britain's most significant goods shipped to the US, which is easily the largest buyer for leading UK drugmakers.
Trade data reveal that in the 12 months leading up to September, the UK exported drugs worth over eleven billion pounds to the US. This amount represented 17.4% of all goods exports in that span.
"This guarantee safeguards jobs, increases capital expenditure and paves the way for the UK to establish itself as a global hub for biotech and pharma," a minister commented.
Specific British Pledges
The agreement involves several specific pledges from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to raise overall NHS spending on medicines from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage drug companies must return to the NHS to stay within budget will be restricted at 15%. Last year, rebates were more than 20%.
Industry Background
The deal comes amid a protracted row between the drug companies and the British authorities over spending levels and NHS adoption.
These tensions were exacerbated by arguments that American customers were paying significantly more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been paused or abandoned, while major expansions have been directed toward projects in the United States.
The Science Minister publicly accepted that the NHS had to spend more on treatments, noting that its spending on drugs had declined as a percentage of its total funding over the last ten years.
